Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SPR | P35270 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.31 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435036 | 1.00 | KMT2A (0.44) | KMT2AMAPTLMNAALDH1A1SPR | |
| SCHEMBL21319702 | 0.88 | KMT2A (0.37) | KMT2AMAPTLMNAALDH1A1HTT | |
| SCHEMBL493850 | 0.81 | MAPT (0.45) | KMT2AMAPTLMNAALDH1A1SPR | |
| SCHEMBL432792 | 0.79 | KMT2A (0.52) | KMT2AMAPTLMNAALDH1A1SPR | |
| SCHEMBL5542753 | 0.71 | KMT2A (0.53) | KMT2AMAPTLMNAALDH1A1HTT | |
| SCHEMBL1817756 | 0.71 | KMT2A (0.40) | KMT2AMAPTLMNASPRHTT | |
| SCHEMBL11430439 | 0.71 | KMT2A (0.52) | KMT2AMAPTLMNAALDH1A1SPR | |
| SCHEMBL493369 | 0.70 | KMT2A (0.45) | KMT2AMAPTLMNAALDH1A1SPR | |
| SCHEMBL493370 | 0.70 | KMT2A (0.45) | KMT2AMAPTLMNAALDH1A1SPR | |
| SCHEMBL1061727 | 0.70 | KMT2A (0.39) | KMT2AMAPTLMNASPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | claimed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | claimed |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2016-09-29 | — | — | US | claimed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | claimed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | claimed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | claimed |
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| US-9676698-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2017-06-13 | — | — | US | disclosed |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2016-09-29 | — | — | US | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | KMT2A 3425/4885MAPT 4025/4885LMNA 4244/4885 |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | KMT2A 3425/4885MAPT 4025/4885LMNA 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.